Emibetuzumab MedChemExpress (MCE)

Product Name	Emibetuzumab
Synonyms	Emibetuzumab
CAS	1365287-97-3
EINECS
Chemical Formula
Molecular Weight
inchi
Package	1 mg;5 mg;10 mg
Price	Email to quote
Descriptions	Emibetuzumab Emibetuzumab MedChemExpress (MCE) HY-P99192 1365287-97-3 LY2875358 95.00% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. Emibetuzumab (LY2875358) (100 nmol/L Descriptions Emibetuzumab Emibetuzumab MedChemExpress (MCE) HY-P99192 1365287-97-3 LY2875358 95.00% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. Emibetuzumab (LY2875358) (100 nmol/L 6 days) inhibits HGF-stimulated proliferation of H596[1]. Emibetuzumab (LY2875358) (10 mg/kg i.v. once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1]. Emibetuzumab (10 or 20 mg/kg i.v. single) downregulates levels of MET and pMET in the tumors of mice[1]. Emibetuzumab (10 mg/kg i.v. once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1]. MET[1]. In Vitro Emibetuzumab (LY2875358) (100 nmol/L 6 days) inhibits HGF-stimulated proliferation of H596[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Emibetuzumab Related Antibodies Cell Proliferation Assay[1] Cell Line: H596 cells (HGF-stimulated) Humanized Human IgG4 kappa Human IgG4 (S228P) kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1 20(23):6059-70. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact